CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 42.461
AS - Asia 18.271
EU - Europa 17.811
SA - Sud America 2.691
AF - Africa 378
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 14
Totale 81.670
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 41.918
GB - Regno Unito 5.584
SG - Singapore 5.344
CN - Cina 5.080
IT - Italia 3.889
HK - Hong Kong 2.270
BR - Brasile 2.085
VN - Vietnam 1.744
SE - Svezia 1.510
DE - Germania 1.297
UA - Ucraina 1.117
FI - Finlandia 1.100
BD - Bangladesh 971
IE - Irlanda 929
TR - Turchia 769
RU - Federazione Russa 655
FR - Francia 623
KR - Corea 462
IN - India 422
BG - Bulgaria 396
CA - Canada 250
ID - Indonesia 231
AR - Argentina 196
MX - Messico 162
IQ - Iraq 138
JP - Giappone 125
NL - Olanda 121
EC - Ecuador 98
ZA - Sudafrica 97
PL - Polonia 90
AE - Emirati Arabi Uniti 88
ES - Italia 83
PK - Pakistan 79
CO - Colombia 77
BE - Belgio 75
VE - Venezuela 61
PH - Filippine 60
CL - Cile 58
UZ - Uzbekistan 53
MY - Malesia 52
SA - Arabia Saudita 51
PY - Paraguay 48
MA - Marocco 47
AU - Australia 42
LT - Lituania 42
EG - Egitto 37
CZ - Repubblica Ceca 36
KE - Kenya 35
NP - Nepal 35
AT - Austria 34
JO - Giordania 32
TH - Thailandia 30
TN - Tunisia 29
AL - Albania 27
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 24
TW - Taiwan 24
UY - Uruguay 24
RO - Romania 23
DZ - Algeria 22
JM - Giamaica 22
BO - Bolivia 21
DO - Repubblica Dominicana 21
RS - Serbia 21
CH - Svizzera 20
PE - Perù 20
IL - Israele 19
OM - Oman 17
PT - Portogallo 17
CR - Costa Rica 16
GR - Grecia 16
HN - Honduras 16
KZ - Kazakistan 16
LB - Libano 16
NG - Nigeria 16
SN - Senegal 14
SI - Slovenia 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
SY - Repubblica araba siriana 10
MD - Moldavia 9
PS - Palestinian Territory 9
QA - Qatar 9
TT - Trinidad e Tobago 9
AM - Armenia 8
BW - Botswana 8
NI - Nicaragua 8
AO - Angola 7
DK - Danimarca 7
MK - Macedonia 7
NO - Norvegia 7
BA - Bosnia-Erzegovina 6
PR - Porto Rico 6
BB - Barbados 5
Totale 81.557
Salva come PNG Salva come JPEG
Città #
Fairfield 4.172
Southend 3.802
Ashburn 3.618
Singapore 3.484
Woodbridge 3.074
Santa Clara 2.912
Houston 2.627
Jacksonville 2.288
Hong Kong 2.239
Chandler 2.036
Ann Arbor 1.736
Dearborn 1.571
Seattle 1.541
Hefei 1.525
Wilmington 1.518
Cambridge 1.376
Beijing 1.010
San Jose 981
London 939
Dublin 924
Nyköping 827
Helsinki 711
Council Bluffs 697
Los Angeles 675
Modena 640
The Dalles 634
Ho Chi Minh City 580
Chicago 561
New York 475
Princeton 444
Milan 438
San Diego 431
Seoul 429
Hanoi 395
Sofia 381
Eugene 379
Izmir 364
Lauterbourg 319
Buffalo 257
Salt Lake City 226
Shanghai 209
Des Moines 206
Moscow 203
Rome 195
São Paulo 192
Columbus 187
Dallas 168
Jakarta 149
Falls Church 142
Munich 138
Boardman 127
Frankfurt am Main 121
Elk Grove Village 116
Tampa 111
Bologna 99
Norwalk 93
Phoenix 90
Tokyo 90
Orem 85
Guangzhou 84
Naples 81
Da Nang 80
Haiphong 71
Atlanta 70
Brussels 67
Miano 66
Lancaster 64
Turin 63
Chennai 62
Denver 62
Mexico City 62
Warsaw 62
Redwood City 58
Toronto 58
Rio de Janeiro 57
Florence 55
Dong Ket 54
Fremont 53
Sterling 52
Belo Horizonte 51
Nanjing 51
Bremen 49
Kunming 49
Porto Alegre 49
Brooklyn 47
Redondo Beach 47
Bari 45
Falkenstein 45
Tashkent 44
Verona 43
Baghdad 41
Brasília 41
Mumbai 40
Montreal 39
Kilburn 38
Miami 38
Stockholm 38
Curitiba 37
Amsterdam 36
Johannesburg 36
Totale 58.142
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.158
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 491
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 440
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 433
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 428
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 427
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 421
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 421
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 411
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 406
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 406
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 402
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 390
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 387
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 382
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 380
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 380
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 378
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 378
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 373
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 370
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 369
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 367
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 365
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 363
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 359
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 354
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 353
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 350
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 349
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 347
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 343
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 341
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 340
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 337
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 336
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 334
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 333
Achievements and unmet needs in the management of advanced ovarian cancer 329
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 325
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 324
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 323
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 322
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 319
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 315
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 314
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 314
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 313
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 311
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 309
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 309
Immune characterization of breast cancer metastases: prognostic implications. 307
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 306
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 305
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 305
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 304
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 302
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 296
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 295
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 293
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 293
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 290
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 289
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 288
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 288
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 285
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 282
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 278
Significance of lymph node sampling in epithelial carcinoma of the ovary. 276
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 273
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 272
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 272
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 271
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 270
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 268
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 266
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 264
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 263
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 262
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 260
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 260
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 259
Device for cell culture 258
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 257
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 256
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 255
Biomarkers predicting clinical benefit: fact or fiction? 253
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 252
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 250
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 249
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 249
A phase II study with danazol in metastatic breast cancer. 249
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 248
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 248
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 247
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 247
Biomarker expression and survival after primary chemotherapy for breast cancer. 245
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 244
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients 242
The curability of breast cancer and the treatment of advanced disease 242
Totale 32.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 309.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 309.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021310 0 0 0 0 0 0 0 0 0 0 0 310
2021/20226.219 88 931 783 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202625.461 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 2.172 1.271
Totale 82.038